跳转至内容
Merck
所有图片(1)

主要文件

SML2860

Sigma-Aldrich

Triptorelin acetate

≥98% (HPLC)

别名:

6-D-Tryptophan-Luteinizing Hormone-Releasing Factor acetate, [D-Trp6]-LH-RH acetate

登录查看公司和协议定价

选择尺寸

5 MG
$136.00
25 MG
$548.00

$136.00

预计发货时间2025年5月23日详情

获取大包装报价
所有图片(1)

选择尺寸

变更视图
5 MG
$136.00
25 MG
$548.00

About This Item

经验公式（希尔记法）:
C64H82N18O13 · xC2H4O2
分子量:
1311.45 (free base basis)
UNSPSC代码:
12352200
NACRES:
NA.77

$136.00

预计发货时间2025年5月23日详情

获取大包装报价

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to off-white

储存温度

−20°C

生化/生理作用

Synthetic LHRH agonist analog
Triptorelin acetate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H360D

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000417755
0000417756
0000417756
0000417755
0000380524

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Successful desensitization to gonadotropin-releasing hormone analogue triptorelin acetate using a sustained-release depot preparation.
Pauline Chan Ng et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 29(6), 660-663 (2018-05-29)
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
Davide Meani et al.
Therapeutic advances in urology, 10(2), 51-63 (2018-02-13)
Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持